We use cookies for a better user experience. Read our Privacy Policy

I Agree

Hemostasis Diagnostics Market

Hemostasis Diagnostics Market (Product Type - Laboratory Systems, Consumables, and Point-of-Care Testing Systems; Test Type - Prothrombin Test Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen Degradation Products (FDP), Activated Clotting Time, Platelet Aggregation Test, and D Dimer; End Users - Hospital/Clinics, Independent Diagnostic Laboratories, and Home Care Settings) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global hemostasis diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period
  • According to the report, the global hemostasis diagnostics market was valued at US$ 2.3 Bn in 2018 and is anticipated to expand at a CAGR of 8.5% from 2019 to 2027

Request a sample to get extensive insights into the Hemostasis Diagnostics Market

Rise in Prevalence of Blood Clotting Disorders and High Prevalence of Cardiovascular Diseases: Key Drivers

  • Bleeding easily when bruised is called abnormal bleeding. It can be due to blood clotting disorder, when the body is unable to produce clotting factors to stop bleeding. Hemophilia A and B, along with factor II, V, VII, X, or XII deficiencies are blood disorders identified with abnormal bleeding issues or blood coagulating issues. Over 440,000 people are suffering from hemophilia globally; of these 75% people are affected in less developed and developing countries
  • In 2018, it was estimated that over 13,600 people in the United States had been diagnosed with hemophilia A, while around 4,100 had been diagnosed with hemophilia B. Hemophilia is more common among males than females, with around 90% of hemophilia A cases worldwide occurring among males.
  • Prevalence of numerous diseases such as cancer, diabetes, and neurological disorders has increased due to rise in geriatric population and changing lifestyle in developing economies. Cardiovascular disease is one of the major factor in this. According to the WHO, cardiovascular diseases account for 17.5 million deaths across the world, which is about 31% of all the deaths globally. Deep vein thrombosis is one of the cardiovascular complications, wherein blood clots are formed within the deep vein, commonly in the legs. According to the CDC, about 900,000 people could be affected each year in the U.S. It is suggested that around 60,000 to 100,000 people in the U.S. die due to this disease.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Advancement in Technology Leading to Easy Usage Boost Market Growth

  • Hemostasis diagnostics devices have come a long way from quantifying optical density of clot in a cuvette to detection of clotting factors. Advancements in hemostasis technology has led to development of wide range of products that have enabled clinicians to provide proper emergency assistance to patients.
  • The concept of automation has extended to hemostasis diagnostics as well, which is less labor intensive, rapid, and easy-to-use. Current technologies include automation of blood coagulation analyzers, flow cytometers, microarrays, and PCR. Combination of these technologies has increased the yield and productivity.
  • This technological revolution in hemostasis diagnostics is expected to propel the market from 2019 to 2027.

High Cost of Automated Instruments to Hamper Market

  • Advancements in technology in hemostasis diagnostics instruments carry a heavy price tag. Laboratories cannot afford high cost instruments. Therefore, there is a need for basic coagulation instruments, which are cost effective and easy-to-use.
  • At a list price of US$ 49,000, the Accuri C6 is in the lower-middle range of benchtop flow cytometer instruments, which start at $14,000 for the closed-architecture Muse Cell Analyzer from EMD Millipore. Most instruments cost $75,000 to $100,000 for a two-laser, four- to six-color instrument.
  •  High instrument cost can increase testing expenditure, which can restrain the global hemostasis diagnostics market during the forecast period

Global Hemostasis Diagnostics Market: Competitive Landscape

  • This report profiles major players in the global hemostasis diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global hemostasis diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global hemostasis diagnostics market are
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Nihon Kohden Corporation
    • Sysmex Corporation
    • Siemens Healthineers
    • Instrumentation Laboratory
    • Danaher Corporation (Beckman Coulter)
    • Grifols
    • S.A. among others

Global Hemostasis diagnostics market: Key Developments

Key players in the global hemostasis diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global hemostasis diagnostics market. A few expansion strategies adopted by players operating in the global hemostasis diagnostics market are:

  • In July 2020, Sysmex Corporation launched of new products in the hemostasis field: the Automated Blood Coagulation Analyzers CN-6500/CN-3500. These new offerings from Sysmex come with a measuring unit using the chemiluminescence enzyme immunoassay methodology (CLEIA), which we cultivated in our Automated Immunoassay Systems HISCL-5000/HISCL-800 (HISCL), on top of the unique features of the Automated Blood Coagulation Analyzers CN-6000/CN-3000, making it possible to measure blood coagulation testing parameters, including molecular markers for blood coagulation with a single device.
  • In May 2018, HORIBA UK Ltd launched new Yumizen G range of instruments and reagents for Haemostasis solutions.
  • In April 2017, Starch Medical Inc. expanded its hemostasis portfolio with launch of SuperClot Hemostat in Europe.

The report on the global hemostasis diagnostics market discussed individual strategies, followed by company profiles of manufacturers of hemostasis diagnostics devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hemostasis diagnostics market.

Hemostasis Diagnostics Market to Observe Growth in High Prevalence of Coagulation Disorders

Coagulation disorders are issues with the body’s capacity to clot blood. These conditions may result in hemorrhage or thrombosis. Coagulatory disorders can be caused by a variety of factors. These conditions may be developed or inherited. Platelet dysfunction, von Willebrand disease, and hemophilia are some of the most common coagulation disorders that can trigger bleeding. In addition to that, disseminated intravascular coagulation, deficiency of Vitamin K, and other clotting factor defects are other causes of coagulation disorders that may lead to bleeding. These factors are likely to work in favor of the global hemostasis diagnostics market in near future. Hemophilia A is four times more common than hemophilia B, as per the National Hemophilia Foundation. In the United States, there are about 20,000 people suffering from hemophilia.

Rapid Technological Progress to Create Ample Opportunities for the Market

Technology progresses at a breakneck rate and it is likely to play an important role in the expansion of the global hemostasis diagnostics market in the years to come. Blood coagulation control has become increasingly important in recent years for assessing bleeding risk in comprehensive surgical procedures and dialysis, diagnosing hemorrhage causes, and designing anticoagulant medications. It is also utilized for determining the effectiveness of hemostatic therapies. From calculating the optical density of a clot in a cuvette to identifying factors of clotting, hemostasis diagnostics have come a long way. Platelet function analyzers, functional assays of particular coagulation proteins, molecular typing immunologic assays, chromogenic assays, and flow cytometry, and are examples of these techniques. These technical developments have resulted in improved sensitivity, accuracy, productivity, and capability, and eventually it leads to better patient clinical care.

There are two types of bleeding disorders: acquired and hereditary. Inherited bleeding disorders are caused by a lack of coagulation factors and are caused by a genetic predisposition. Circumstances that can occur at any point of time during a person's lifespan can induce acquired bleeding disorders. Hereditary bleeding disorders are caused by a lack or deficiency of particular clotting proteins, which function as procoagulants in the clotting cascade by precise interactions. Such factors are estimated to benefit global hemostasis diagnostics market in near future.

Global Hemostasis Diagnostics Market - Segmentation

Product Type

  • Laboratory Systems
  • Consumables
  • Point-of-Care Testing Systems

Product Type

  • Prothrombin Test Time (PT)
  • Activated partial thromboplastin time (APTT)
  • Fibrinogen degradation products (FDP)
  • Activated Clotting Time
  • Platelet Aggregation Test
  • D Dimer
  • Others

End-user

  • Hospital/Clinics
  • Independent Diagnostic Laboratories
  • Home Care Settings
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of hemostasis diagnostics market?

The global hemostasis diagnostics market was worth US$ 2.3 Bn and is projected to reach a value of US$ 4.7 Bn by the end of 2027

What is the anticipated CAGR of the hemostasis diagnostics market in the forecast period?

Hemostasis diagnostics market is anticipated to grow at a CAGR of 8.5% during the forecast period

Which region is expected to project the highest market share in the global hemostasis diagnostics market?

North America accounted for a major share of the global hemostasis diagnostics market

What are the key driving factors for the growth of the hemostasis diagnostics market?

Hemostasis Diagnostics Market is driven by rise in prevalence of blood clotting disorders and high prevalence of cardiovascular diseases

Who are the key players in the global hemostasis diagnostics market?

Key players in the global hemostasis diagnostics market include Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Sysmex Corporation, Siemens Healthineers, Instrumentation Laboratory, Danaher Corporation (Beckman Coulter), and Grifols, S.A.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Hemostasis Diagnostics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Hemostasis Diagnostics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Coagulation Disorders & Coagulation Pathways: Overview

    5.2. Epidemiology: Coagulation Disorders

    5.3. Regulatory Framework

    5.4. Reimbursement Scenario

    5.5. Hemostasis Diagnostics Market: Pricing Analysis

    5.6. Hemostasis Diagnostics Market: Value Chain Analysis

    5.7. Hemostasis Diagnostics Market: Porter’s Five Forces Analysis

6. Global Hemostasis Diagnostics Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Hemostasis Diagnostics Market Value Forecast, by Product Type, 2017–2027

        6.2.1. Laboratory Systems

            6.2.1.1. Automated Systems

            6.2.1.2. Semi-automated Systems

            6.2.1.3. Manual Systems

        6.2.2. Consumables

        6.2.3. Point-of-Care Testing Systems

    6.3. Global Hemostasis Diagnostics Market Attractiveness, by Product Type

7. Global Hemostasis Diagnostics Market Analysis and Forecast, by Test Type

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Hemostasis Diagnostics Market Value Forecast, by Test Type, 2017–2027

        7.2.1. Prothrombin Test Time (PT)

        7.2.2. Activated partial thromboplastin time (APTT)

        7.2.3. Fibrinogen degradation products (FDP)

        7.2.4. Activated Clotting Time

        7.2.5. Platelet Aggregation Test

        7.2.6. D Dimer

        7.2.7. Others

    7.3. Global Hemostasis Diagnostics Market Attractiveness, by Test Type

8. Global Hemostasis Diagnostics Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Hemostasis Diagnostics Market Value Forecast, by End-user, 2017–2027

        8.2.1. Hospital/Clinics

        8.2.2. Independent Diagnostic Laboratories

        8.2.3. Home Care Settings

        8.2.4. Others

    8.3. Global Hemostasis Diagnostics Market Attractiveness, by End-user

9. Global Hemostasis Diagnostics Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Hemostasis Diagnostics Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. North America Hemostasis Diagnostics Market Attractiveness, by Region

10. North America Hemostasis Diagnostics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

        10.2.1. Laboratory Systems

            10.2.1.1. Automated Systems

            10.2.1.2. Semi-automated Systems

            10.2.1.3. Manual Systems

        10.2.2. Consumables

        10.2.3. Point-of-Care Testing Systems

    10.3. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        10.3.1. Prothrombin Test Time (PT)

        10.3.2. Activated partial thromboplastin time (APTT)

        10.3.3. Fibrinogen degradation products (FDP)

        10.3.4. Activated Clotting Time

        10.3.5. Platelet Aggregation Test

        10.3.6. D Dimer

        10.3.7. Others

    10.4. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

        10.4.1. Hospital/Clinics

        10.4.2. Independent Diagnostic Laboratories

        10.4.3. Home Care Settings

        10.4.4. Others

    10.5. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Hemostasis Diagnostics Market Attractiveness Analysis

        10.6.1. By Product Type

        10.6.2. By Test Type

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Hemostasis Diagnostics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

        11.2.1. Laboratory Systems

            11.2.1.1. Automated Systems

            11.2.1.2. Semi-automated Systems

            11.2.1.3. Manual Systems

        11.2.2. Consumables

        11.2.3. Point-of-Care Testing Systems

    11.3. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        11.3.1. Prothrombin Test Time (PT)

        11.3.2. Activated partial thromboplastin time (APTT)

        11.3.3. Fibrinogen degradation products (FDP)

        11.3.4. Activated Clotting Time

        11.3.5. Platelet Aggregation Test

        11.3.6. D Dimer

        11.3.7. Others

    11.4. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

        11.4.1. Hospital/Clinics

        11.4.2. Independent Diagnostic Laboratories

        11.4.3. Home Care Settings

        11.4.4. Others

    11.5. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Hemostasis Diagnostics Market Attractiveness Analysis

        11.6.1. By Product Type

        11.6.2. By Test Type

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Hemostasis Diagnostics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

        12.2.1. Laboratory Systems

            12.2.1.1. Automated Systems

            12.2.1.2. Semi-automated Systems

            12.2.1.3. Manual Systems

        12.2.2. Consumables

        12.2.3. Point-of-Care Testing Systems

    12.3. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        12.3.1. Prothrombin Test Time (PT)

        12.3.2. Activated partial thromboplastin time (APTT)

        12.3.3. Fibrinogen degradation products (FDP)

        12.3.4. Activated Clotting Time

        12.3.5. Platelet Aggregation Test

        12.3.6. D Dimer

        12.3.7. Others

    12.4. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

        12.4.1. Hospital/Clinics

        12.4.2. Independent Diagnostic Laboratories

        12.4.3. Home Care Settings

        12.4.4. Others

    12.5. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis

        12.6.1. By Product Type

        12.6.2. By Test Type

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Hemostasis Diagnostics Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

        13.2.1. Laboratory Systems

            13.2.1.1. Automated Systems

            13.2.1.2. Semi-automated Systems

            13.2.1.3. Manual Systems

        13.2.2. Consumables

        13.2.3. Point-of-Care Testing Systems

    13.3. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        13.3.1. Prothrombin Test Time (PT)

        13.3.2. Activated partial thromboplastin time (APTT)

        13.3.3. Fibrinogen degradation products (FDP)

        13.3.4. Activated Clotting Time

        13.3.5. Platelet Aggregation Test

        13.3.6. D Dimer

        13.3.7. Others

    13.4. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

        13.4.1. Hospital/Clinics

        13.4.2. Independent Diagnostic Laboratories

        13.4.3. Home Care Settings

        13.4.4. Others

    13.5. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America Latin America

    13.6. Latin America Hemostasis Diagnostics Market Attractiveness Analysis

        13.6.1. By Product Type

        13.6.2. By Test Type

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Hemostasis Diagnostics Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017–2027

        14.2.1. Laboratory Systems

            14.2.1.1. Automated Systems

            14.2.1.2. Semi-automated Systems

            14.2.1.3. Manual Systems

        14.2.2. Consumables

        14.2.3. Point-of-Care Testing Systems

    14.3. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2027

        14.3.1. Prothrombin Test Time (PT)

        14.3.2. Activated partial thromboplastin time (APTT)

        14.3.3. Fibrinogen degradation products (FDP)

        14.3.4. Activated Clotting Time

        14.3.5. Platelet Aggregation Test

        14.3.6. D Dimer

        14.3.7. Others

    14.4. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2027

        14.4.1. Hospital/Clinics

        14.4.2. Independent Diagnostic Laboratories

        14.4.3. Home Care Settings

        14.4.4. Others

    14.5. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis

        14.6.1. By Product Type

        14.6.2. By Test Type

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by Tier and Size of companies)

    15.2. Market Share / Position Analysis, by Company, 2018

    15.3. Competitive Business Strategies

    15.4. Company Profiles

        15.4.1. Abbott Laboratories, Inc.

            15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.1.2. Financial Analysis

            15.4.1.3. Growth Strategies

            15.4.1.4. SWOT Analysis

        15.4.2. Thermo Fisher Scientific, Inc

            15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.2.2. Financial Analysis

            15.4.2.3. Growth Strategies

            15.4.2.4. SWOT Analysis

        15.4.3. F. Hoffmann-La Roche Ltd  

            15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.3.2. Financial Analysis

            15.4.3.3. Growth Strategies

            15.4.3.4. SWOT Analysis

        15.4.4. Nihon Kohden Corporation  

            15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.4.2. Financial Analysis

            15.4.4.3. Growth Strategies

            15.4.4.4. SWOT Analysis

        15.4.5. Sysmex Corporation

            15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.5.2. Financial Analysis

            15.4.5.3. Growth Strategies

            15.4.5.4. SWOT Analysis

        15.4.6. Siemens Healthineers

            15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.6.2. Financial Analysis

            15.4.6.3. Growth Strategies

            15.4.6.4. SWOT Analysis

        15.4.7. Instrumentation Laboratory

            15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.7.2. Financial Analysis

            15.4.7.3. Growth Strategies

            15.4.7.4. SWOT Analysis

        15.4.8. Danaher Corporation (Beckman Coulter)

            15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.8.2. Financial Analysis

            15.4.8.3. Growth Strategies

            15.4.8.4. SWOT Analysis

        15.4.9. Grifols, S.A.

            15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.9.2. Growth Strategies

            15.4.9.3. SWOT Analysis

List of Table

Table 01: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 02: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017–2027

Table 03: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2027

Table 04: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Region, 2019–2027

Table 05: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 06: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019–2027

Table 07: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019–2027

Table 08: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 09: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 10: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019–2027

Table 11: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019–2027

Table 12: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 13: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019–2027

Table 14: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019–2027

Table 15: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019–2027

Table 16: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019–2027

Table 17: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2017–2027

Table 18: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017–2027

Table 19: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019–2027

Table 20: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 21: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2017–2027

Table 22: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017–2027

Table 23: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019–2027

Table 24: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

List of Figure

Figure 01: Hemostasis Diagnostics Market Snapshot

Figure 02: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 03: Market Value Share By Product (2018)

Figure 04: Market Value Share By End-user (2018)

Figure 05: Market Value Share By Region(2018)

Figure 06: Global Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 07: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laboratory Systems, 2017–2027

Figure 08: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Consumables, 2017–2027

Figure 09: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Point-of-care Testing Systems, 2017–2027

Figure 10: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Automated Systems, 2017–2027

Figure 11: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Semi-automated Systems, 2017–2027

Figure 12: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Manual Systems, 2017–2027

Figure 13: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Product

Figure 14: Global Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 15: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prothrombin Time (PT), 2017–2027

Figure 16: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by APTT, 2017–2027

Figure 17: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fibrinogen Degradation Products (FDP), 2017–2027

Figure 18: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Activated Clotting Time, 2017–2027

Figure 19: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Platelet Aggregation Test, 2017–2027

Figure 20: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by D Dimer, 2017–2027

Figure 21: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 22: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

Figure 23: Global Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 24: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital & Clinics, 2017–2027

Figure 25: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Diagnostic Laboratories, 2017–2027

Figure 26: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Home Care Settings, 2017–2027

Figure 27: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 28: Global Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

Figure 29: Global Hemostasis Diagnostics Market Value Share Analysis, by Region, 2018 and 2027

Figure 30: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Region

Figure 31: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2019–2027

Figure 32: North America Hemostasis Diagnostics Market Attractiveness Analysis, by Country

Figure 33: North America Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 34: North America Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 35: North America Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 36: North America Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 37: North America Hemostasis Diagnostics Market Attractiveness, by Product

Figure 38: North America Hemostasis Diagnostics Market Attractiveness, by Test Type

Figure 39: North America Hemostasis Diagnostics Market Attractiveness, by End-user

Figure 40: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2019–2027

Figure 41: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Country

Figure 42: Europe Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 43: Europe Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 44: Europe Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 45: Europe Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 46: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Product

Figure 47: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

Figure 48: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

Figure 49: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017– 2027

Figure 50: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Country 2019–2027

Figure 51: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 52: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 53: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 54: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

Figure 55: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Product

Figure 56: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

Figure 57: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

Figure 58: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027

Figure 59: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 60: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 61: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 62: Latin America Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 63: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 64: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Product

Figure 65: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

Figure 66: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

Figure 67: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2017–2027

Figure 68: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Country/Sub-region

Figure 69: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

Figure 70: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

Figure 71: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

Figure 72: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 73: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Product

Figure 74: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

Figure 75: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

Figure 76: Global Hemostasis Diagnostics Market Share Analysis, by Company (2018)

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved